Revenues inched up 1% at the French pharma giant, which is still in the early stages of a five-year turnaround plan launched by CEO Paul Hudson, who took the reins at Sanofi in late 2019. That means aggressive cost-cutting, and leaning into strengths like its world-leading flu vaccine division. The company is also looking for other uses and billions in sales from its eczema drug Dupixent. Despite its flu vaccine dominance, Sanofi has lagged in the COVID vaccine race, with its two candidates still in trials. The company is also reorienting its development pipeline around flourishing areas like oncology and immunology. Sanofi’s profits surged 346.8% thanks to its divestment of its stake in Regeneron, the U.S. biotech.
Lists ranking Sanofi
Latest news for Sanofi
- HealthIts COVID-19 vaccine bogged down in trials, Sanofi to manufacture BioNTech/Pfizer dosesSeptember 10, 2021 1:06 PM UTC
- HealthBooster shots and a big jump in market value: 3 takeaways from Moderna’s Q2 earningsAugust 5, 2021 9:32 PM UTC
- HealthThese four COVID-19 vaccines could soon join the pandemic fightMay 8, 2021 12:00 PM UTC